<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03434249</url>
  </required_header>
  <id_info>
    <org_study_id>PSC-DS BIGI</org_study_id>
    <nct_id>NCT03434249</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy of Bifidobacterium BB-12® in the Treatment of Infantile Colic</brief_title>
  <official_title>Studio Clinico Randomizzato Per Valutare l'Efficacia Del Bifidobacterium BB-12® Nel Trattamento Delle Coliche Infantili</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SOFAR S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SOFAR S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, double blind controlled study to investigate the effects
      of Bifidobacterium, BB-12® versus placebo in a study group of pediatric patients with
      infantile colic.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 11, 2016</start_date>
  <completion_date type="Actual">November 6, 2017</completion_date>
  <primary_completion_date type="Actual">November 6, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a prospective randomized double blind placebo controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With &gt;=50% Reduction in Mean Weekly Crying Duration</measure>
    <time_frame>at 28 days from the baseline (Visit T5)</time_frame>
    <description>Treatment success rate was evaluated in terms of reduction of crying duration, comparing mean weekly duration of the last Week (from T4 to T5) and mean weekly duration of Week 1 (from T0 to T1). The daily number and duration of crying episodes has been collected in the 'Evaluation of crying' section of the patient diary.
Weekly mean is defined as the mean of the calculated average daily durations during the selected week and is described by means of descriptive statistics for continuous data. Mean changes from baseline (i.e. mean of the first Week) to the mean of the selected week will be computed as well.
The following categories of patients has been defined:
Success = patients who meet the criteria for the treatment success rate No Success = patients who do not meet the criteria for the treatment success rate Missing = patients who did not do the last visit (Visit T5 - at 28 days from baseline)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Crying Episodes</measure>
    <time_frame>at 7 days (Visit T1 - baseline) and 28 days from the baseline (Visit T5)</time_frame>
    <description>Weekly mean of cries will be defined as the mean number of cries reported in the &quot;Evaluation of behavior&quot; section during the week (i.e. number of episodes/number of days with episodes) and will be described by means of descriptive statistics for continuous data.
Mean changes from baseline (i.e. mean of the first Week) to the mean of the selected week will be analyzed too.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious Diseases Incidence</measure>
    <time_frame>at each visit, for 5 weeks starting from the enrollment in the study (Visit T0, T1, T2, T3, T4 and T5)</time_frame>
    <description>Number of infections in respiratory system, gastrointestinal system, urinary tract and skin.
An infection was defined as an Adverse Event with SOC equal to &quot;Infections and Infestations&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel Evacuation - Stool Frequency</measure>
    <time_frame>at each weekly visit from baseline (Visit T1, T2, T3, T4 and T5)</time_frame>
    <description>Daily frequency of bowel evacuation. The frequency of stools were collected daily in the diary. Stool frequency was evaluated as the mean of total daily stools reported per week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel Evacuation - Stool Consistency</measure>
    <time_frame>at each weekly visit from baseline (Visit T1, T2, T3, T4 and T5)</time_frame>
    <description>Stool consistency was evaluated as the number and the proportion of patients who reported at least one stool sample of each type per week, according to Bristol scale as follows:
Type A = separate hard lumps, like nuts (hard to pass) Type B = sausage-shaped, but lumpy Type C = Like a sausage but with cracks on its surface Type D = like a sausage or snake, smooth and soft Only a descriptive statistics Type E = soft blobs with clear-cut edges (passed easily) Type F = fluffy pieces with ragged edges, a mushy stool Type G = watery, no solid pieces (entirely liquid). Patients could report more than one stool consistency per day then the sum of the &quot;Count of Participants&quot; for each group at each visit could be Greater then the &quot;Overall Number of Participants Analyzed&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant's Mood</measure>
    <time_frame>at each weekly visit from baseline (Visit T1, T2, T3, T4 and T5)</time_frame>
    <description>The infant's mood (calm, asleep, agitated, irritable) was collected daily in the diary and was evaluated as the number and the proportion of infants who reported at least one mood of each type per week.
Patients could report more than one mood per day then the sum of the &quot;Count of Participants&quot; for each group at each visit could be greater then the &quot;Overall Number of Participants Analyzed&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant's Sleep</measure>
    <time_frame>at each weekly visit from baseline (Visit T1, T2, T3, T4 and T5)</time_frame>
    <description>Duration of sleep (in minutes) was collected daily in the diary during the entire study period. Mean daily duration of sleep by week was defined as the mean of the daily durations during the selected week and was described by means of descriptive statistics for continuous data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant's Temper</measure>
    <time_frame>at each weekly visit from baseline (Visit T1, T2, T3, T4 and T5)</time_frame>
    <description>Duration of temper episodes (in minutes) was collected daily in the diary during the entire study period. Mean daily duration of temper episodes by week was defined as the mean of the daily durations during the selected week and was described by means of descriptive statistics for continuous data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant's Feeding</measure>
    <time_frame>at each weekly visit from baseline (Visit T1, T2, T3, T4 and T5)</time_frame>
    <description>Duration of feeding (in minutes) was collected daily in the diary during the entire study period. Mean daily feeding time by week was defined as the mean of the daily durations during the selected week and was described by means of descriptive statistics for continuous data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calprotectin</measure>
    <time_frame>at 7 days (Visit T1 - baseline) and 28 days from the baseline (Visit T5)</time_frame>
    <description>Evaluation of calprotectin levels in fecal samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta-defensin Type 2</measure>
    <time_frame>at 7 days (Visit T1 - baseline) and 28 days from the baseline (Visit T5)</time_frame>
    <description>Evaluation of Beta-defensin type 2 levels in fecal samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LL37 Peptide</measure>
    <time_frame>at 7 days (Visit T1 - baseline) and 28 days from the baseline (Visit T5)</time_frame>
    <description>Evaluation of LL37 peptide levels in fecal samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Chain Fatty Acids - Butyrate</measure>
    <time_frame>at 7 days (Visit T1 - baseline) and 28 days from the baseline (Visit T5)</time_frame>
    <description>Evaluation of Butyrate levels in fecal samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secretory Immunoglobulin A (SIgA)</measure>
    <time_frame>at 7 days (Visit T1 - baseline) and 28 days from the baseline (Visit T5)</time_frame>
    <description>Secretory immunoglobulin A (SIgA) levels in fecal samples</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Infantile Colic</condition>
  <condition>Colic, Infantile</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacterium, BB-12® (Bifidolactis Infant)</intervention_name>
    <arm_group_label>Group I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidolactis Infant Placebo</intervention_name>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients are included in the study if they meet all the following criteria:

          -  Exclusively breastfed healthy infants of both sexes, aged ≤ 7 weeks.

          -  Diagnosis of IC according to Rome III criteria.

          -  Written informed consent of the parent/tutor.

        Exclusion Criteria:

        Patients are excluded from this study if they meet any of the following criteria:

          -  Birth weight &lt; 2500 g.

          -  Gestational age &lt; 37 weeks.

          -  APGAR 5 minutes &lt; 7.

          -  Formula feeding.

          -  Stunting/loss of weight (&lt; 100 g/weeks from birth to the last reported weight).

          -  Neurological diseases.

          -  Known or suspected food allergy.

          -  Gastroesophageal reflux disease.

          -  Use of substances that alter gut microbiota (probiotics, prebiotics, antibiotics,
             gastric acidity inhibitors) in the last 2 weeks prior the enrollment.

          -  History of fever and/or infectious diseases in the last 2 weeks prior to enrollment.

          -  Ongoing systemic infections.

          -  History of congenital infections.

          -  Chronic intestinal diseases (cystic fibrosis or other forms of primitive pancreatic
             insufficiency)

          -  Primitive or secondary malformations of the gastrointestinal tract (such as esophageal
             atresia, intestinal atresia, short bowel syndrome, malrotation).

          -  Metabolic diseases.

          -  Genetic diseases and chromosomal abnormalities.

          -  Primary or secondary immunodeficiencies.

          -  Not sufficient reliability or presence of conditions that may result in
             non-compliance/adherence of the patient to the Protocol.

          -  Previous participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Berni Canani, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federico II University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dipartimento di Scienze Mediche Traslazionali - Sezione Pediatria - Università degli Studi di napoli &quot;Federico II&quot;</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Hyman PE, Milla PJ, Benninga MA, Davidson GP, Fleisher DF, Taminiau J. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology. 2006 Apr;130(5):1519-26. Review.</citation>
    <PMID>16678565</PMID>
  </reference>
  <reference>
    <citation>Szajewska H, Gyrczuk E, Horvath A. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2013 Feb;162(2):257-62. doi: 10.1016/j.jpeds.2012.08.004. Epub 2012 Sep 14.</citation>
    <PMID>22981952</PMID>
  </reference>
  <reference>
    <citation>Kabeerdoss J, Devi RS, Mary RR, Prabhavathi D, Vidya R, Mechenro J, Mahendri NV, Pugazhendhi S, Ramakrishna BS. Effect of yoghurt containing Bifidobacterium lactis Bb12® on faecal excretion of secretory immunoglobulin A and human beta-defensin 2 in healthy adult volunteers. Nutr J. 2011 Dec 23;10:138. doi: 10.1186/1475-2891-10-138.</citation>
    <PMID>22196482</PMID>
  </reference>
  <reference>
    <citation>Mohan R, Koebnick C, Schildt J, Mueller M, Radke M, Blaut M. Effects of Bifidobacterium lactis Bb12 supplementation on body weight, fecal pH, acetate, lactate, calprotectin, and IgA in preterm infants. Pediatr Res. 2008 Oct;64(4):418-22. doi: 10.1203/PDR.0b013e318181b7fa.</citation>
    <PMID>18552710</PMID>
  </reference>
  <reference>
    <citation>Mohan R, Koebnick C, Schildt J, Schmidt S, Mueller M, Possner M, Radke M, Blaut M. Effects of Bifidobacterium lactis Bb12 supplementation on intestinal microbiota of preterm infants: a double-blind, placebo-controlled, randomized study. J Clin Microbiol. 2006 Nov;44(11):4025-31. Epub 2006 Sep 13.</citation>
    <PMID>16971641</PMID>
  </reference>
  <reference>
    <citation>Savino F, Cordisco L, Tarasco V, Calabrese R, Palumeri E, Matteuzzi D. Molecular identification of coliform bacteria from colicky breastfed infants. Acta Paediatr. 2009 Oct;98(10):1582-8. doi: 10.1111/j.1651-2227.2009.01419.x. Epub 2009 Jul 9.</citation>
    <PMID>19604166</PMID>
  </reference>
  <reference>
    <citation>Hall B, Chesters J, Robinson A. Infantile colic: a systematic review of medical and conventional therapies. J Paediatr Child Health. 2012 Feb;48(2):128-37. doi: 10.1111/j.1440-1754.2011.02061.x. Epub 2011 Apr 7. Review.</citation>
    <PMID>21470331</PMID>
  </reference>
  <reference>
    <citation>Savino F, Bailo E, Oggero R, Tullio V, Roana J, Carlone N, Cuffini AM, Silvestro L. Bacterial counts of intestinal Lactobacillus species in infants with colic. Pediatr Allergy Immunol. 2005 Feb;16(1):72-5.</citation>
    <PMID>15693915</PMID>
  </reference>
  <reference>
    <citation>Savino F, Cresi F, Pautasso S, Palumeri E, Tullio V, Roana J, Silvestro L, Oggero R. Intestinal microflora in breastfed colicky and non-colicky infants. Acta Paediatr. 2004 Jun;93(6):825-9.</citation>
    <PMID>15244234</PMID>
  </reference>
  <reference>
    <citation>Gupta SK. Is colic a gastrointestinal disorder? Curr Opin Pediatr. 2002 Oct;14(5):588-92. Review.</citation>
    <PMID>12352253</PMID>
  </reference>
  <reference>
    <citation>Lucassen PL, Assendelft WJ, van Eijk JT, Gubbels JW, Douwes AC, van Geldrop WJ. Systematic review of the occurrence of infantile colic in the community. Arch Dis Child. 2001 May;84(5):398-403. Review.</citation>
    <PMID>11316682</PMID>
  </reference>
  <reference>
    <citation>BRAZELTON TB. Crying in infancy. Pediatrics. 1962 Apr;29:579-88.</citation>
    <PMID>13872677</PMID>
  </reference>
  <reference>
    <citation>Iacovou M, Ralston RA, Muir J, Walker KZ, Truby H. Dietary management of infantile colic: a systematic review. Matern Child Health J. 2012 Aug;16(6):1319-31. doi: 10.1007/s10995-011-0842-5. Review.</citation>
    <PMID>21710185</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>February 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2018</study_first_posted>
  <results_first_submitted>December 4, 2019</results_first_submitted>
  <results_first_submitted_qc>January 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 23, 2020</results_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bifidobacterium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT03434249/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT03434249/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was a randomized, double-blind, placebo-controlled parallel-group study. Eighty (80) infants were screened and all were enrolled in the study and randomized (40 to Bifidobacteriium BB-12® and 40 to Placebo).
The enrollment period started on 11-Nov-2016 and closed on 6-Nov-2017.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Bifidobacterium BB-12®</title>
          <description>patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance of family</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Difficulties in completing daily diary</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bifidobacterium BB-12®</title>
          <description>patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
Bifidobacterium, BB-12® (Bifidolactis Infant)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
Bifidolactis Infant Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.05" spread="5.03"/>
                    <measurement group_id="B2" value="32.73" spread="5.69"/>
                    <measurement group_id="B3" value="32.89" spread="5.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of childbirth</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Caesarean section</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Natural childbirth</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational age</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.43" spread="0.93"/>
                    <measurement group_id="B2" value="38.53" spread="1.20"/>
                    <measurement group_id="B3" value="38.48" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birth weight</title>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3280.75" spread="367.54"/>
                    <measurement group_id="B2" value="3412.00" spread="442.75"/>
                    <measurement group_id="B3" value="3346.38" spread="409.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apgar 5 minutes score</title>
          <description>The Apgar score (APGAR is the acronym of Appearance, Pulse, Grimace, Activity, Respiration) is a method used to summarize the health of newborn children. It evaluates five parameters (Skin colors, Pulse rate, Reflex irritability grimace, Muscle tone, Respiratory effort) assigning to each parameter a score from 0 to 2 (values 0, 1, 2) and summing up the five values. The resulting score ranges from 0 to 10. APGAR 5 minutes means that the test is done at 5 minutes after birth. Scores &gt; 7 are considered normal; 4 to 6, fairly low; and &lt; 3 are generally regarded as critically low.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.95" spread="0.39"/>
                    <measurement group_id="B2" value="8.83" spread="0.38"/>
                    <measurement group_id="B3" value="8.89" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Positive family history of allergic disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Positive family history of functional gastrointestinal diseases</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical/surgical history</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No prior clinical/surgical events were reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Prior clinical/surgical events were reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Exposure to second-hand tobacco smoke within the home environment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking habits</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Mother</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mother, Father</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Father</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No one</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With &gt;=50% Reduction in Mean Weekly Crying Duration</title>
        <description>Treatment success rate was evaluated in terms of reduction of crying duration, comparing mean weekly duration of the last Week (from T4 to T5) and mean weekly duration of Week 1 (from T0 to T1). The daily number and duration of crying episodes has been collected in the 'Evaluation of crying' section of the patient diary.
Weekly mean is defined as the mean of the calculated average daily durations during the selected week and is described by means of descriptive statistics for continuous data. Mean changes from baseline (i.e. mean of the first Week) to the mean of the selected week will be computed as well.
The following categories of patients has been defined:
Success = patients who meet the criteria for the treatment success rate No Success = patients who do not meet the criteria for the treatment success rate Missing = patients who did not do the last visit (Visit T5 - at 28 days from baseline)</description>
        <time_frame>at 28 days from the baseline (Visit T5)</time_frame>
        <population>Intention to Treat Set (ITT): all randomized patients who received at least one dose of study treatment. Following the intent-to-treat (ITT) principle, patients were analyzed according to the treatment they were assigned to at the randomization visit.
Patients drop-out were also considered and classified as Treatment success rate = &quot;Missing&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Bifidobacterium BB-12®</title>
            <description>patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
Bifidobacterium, BB-12® (Bifidolactis Infant)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
Bifidolactis Infant Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With &gt;=50% Reduction in Mean Weekly Crying Duration</title>
          <description>Treatment success rate was evaluated in terms of reduction of crying duration, comparing mean weekly duration of the last Week (from T4 to T5) and mean weekly duration of Week 1 (from T0 to T1). The daily number and duration of crying episodes has been collected in the 'Evaluation of crying' section of the patient diary.
Weekly mean is defined as the mean of the calculated average daily durations during the selected week and is described by means of descriptive statistics for continuous data. Mean changes from baseline (i.e. mean of the first Week) to the mean of the selected week will be computed as well.
The following categories of patients has been defined:
Success = patients who meet the criteria for the treatment success rate No Success = patients who do not meet the criteria for the treatment success rate Missing = patients who did not do the last visit (Visit T5 - at 28 days from baseline)</description>
          <population>Intention to Treat Set (ITT): all randomized patients who received at least one dose of study treatment. Following the intent-to-treat (ITT) principle, patients were analyzed according to the treatment they were assigned to at the randomization visit.
Patients drop-out were also considered and classified as Treatment success rate = &quot;Missing&quot;.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit T5 - Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T5 - No Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T5 - Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>According to the results of a previous trial that looked at a probiotic’s effect on infants with CI, it was estimated that when the sample size in each group is 33, the study has 80% power to detect an absolute difference of 35% in the treatment success rate (15% in the Placebo group and 50% in the treatment group) with a 0,05 alpha level.
The number of infants that was included in the study was 80, with an expected maximum dropout rate of 20%.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Crying Episodes</title>
        <description>Weekly mean of cries will be defined as the mean number of cries reported in the &quot;Evaluation of behavior&quot; section during the week (i.e. number of episodes/number of days with episodes) and will be described by means of descriptive statistics for continuous data.
Mean changes from baseline (i.e. mean of the first Week) to the mean of the selected week will be analyzed too.</description>
        <time_frame>at 7 days (Visit T1 - baseline) and 28 days from the baseline (Visit T5)</time_frame>
        <population>Intention to Treat Set (ITT): all randomized patients who received at least one dose of study treatment.
The number of participants analyzed in Visit T5 is less then Visit T1 since 8 participants dropped from the study before Visit T5</population>
        <group_list>
          <group group_id="O1">
            <title>Bifidobacterium BB-12®</title>
            <description>patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
Bifidobacterium, BB-12® (Bifidolactis Infant)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
Bifidolactis Infant Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Crying Episodes</title>
          <description>Weekly mean of cries will be defined as the mean number of cries reported in the &quot;Evaluation of behavior&quot; section during the week (i.e. number of episodes/number of days with episodes) and will be described by means of descriptive statistics for continuous data.
Mean changes from baseline (i.e. mean of the first Week) to the mean of the selected week will be analyzed too.</description>
          <population>Intention to Treat Set (ITT): all randomized patients who received at least one dose of study treatment.
The number of participants analyzed in Visit T5 is less then Visit T1 since 8 participants dropped from the study before Visit T5</population>
          <units>number of episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit T1 - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.92" spread="2.79"/>
                    <measurement group_id="O2" value="8.28" spread="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.15" spread="1.48"/>
                    <measurement group_id="O2" value="6.04" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infectious Diseases Incidence</title>
        <description>Number of infections in respiratory system, gastrointestinal system, urinary tract and skin.
An infection was defined as an Adverse Event with SOC equal to &quot;Infections and Infestations&quot;.</description>
        <time_frame>at each visit, for 5 weeks starting from the enrollment in the study (Visit T0, T1, T2, T3, T4 and T5)</time_frame>
        <population>Intention to Treat Set (ITT): all randomized patients who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Bifidobacterium BB-12®</title>
            <description>patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
Bifidobacterium, BB-12® (Bifidolactis Infant)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
Bifidolactis Infant Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Infectious Diseases Incidence</title>
          <description>Number of infections in respiratory system, gastrointestinal system, urinary tract and skin.
An infection was defined as an Adverse Event with SOC equal to &quot;Infections and Infestations&quot;.</description>
          <population>Intention to Treat Set (ITT): all randomized patients who received at least one dose of study treatment.</population>
          <units>Number of infections</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bowel Evacuation - Stool Frequency</title>
        <description>Daily frequency of bowel evacuation. The frequency of stools were collected daily in the diary. Stool frequency was evaluated as the mean of total daily stools reported per week.</description>
        <time_frame>at each weekly visit from baseline (Visit T1, T2, T3, T4 and T5)</time_frame>
        <population>Intention to Treat Set (ITT): all randomized patients who received at least one dose of study treatment.
The number of participants analyzed in Visit T5 is less then Visit T1 since 8 participants dropped from the study before Visit T5</population>
        <group_list>
          <group group_id="O1">
            <title>Bifidobacterium BB-12®</title>
            <description>patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
Bifidobacterium, BB-12® (Bifidolactis Infant)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
Bifidolactis Infant Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Bowel Evacuation - Stool Frequency</title>
          <description>Daily frequency of bowel evacuation. The frequency of stools were collected daily in the diary. Stool frequency was evaluated as the mean of total daily stools reported per week.</description>
          <population>Intention to Treat Set (ITT): all randomized patients who received at least one dose of study treatment.
The number of participants analyzed in Visit T5 is less then Visit T1 since 8 participants dropped from the study before Visit T5</population>
          <units>daily number of bowel evacuations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visti T1 - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.30" spread="1.49"/>
                    <measurement group_id="O2" value="5.61" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.15" spread="1.63"/>
                    <measurement group_id="O2" value="5.50" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.92" spread="1.53"/>
                    <measurement group_id="O2" value="5.35" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.51" spread="1.51"/>
                    <measurement group_id="O2" value="5.10" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.34" spread="1.45"/>
                    <measurement group_id="O2" value="4.64" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bowel Evacuation - Stool Consistency</title>
        <description>Stool consistency was evaluated as the number and the proportion of patients who reported at least one stool sample of each type per week, according to Bristol scale as follows:
Type A = separate hard lumps, like nuts (hard to pass) Type B = sausage-shaped, but lumpy Type C = Like a sausage but with cracks on its surface Type D = like a sausage or snake, smooth and soft Only a descriptive statistics Type E = soft blobs with clear-cut edges (passed easily) Type F = fluffy pieces with ragged edges, a mushy stool Type G = watery, no solid pieces (entirely liquid). Patients could report more than one stool consistency per day then the sum of the &quot;Count of Participants&quot; for each group at each visit could be Greater then the &quot;Overall Number of Participants Analyzed&quot;</description>
        <time_frame>at each weekly visit from baseline (Visit T1, T2, T3, T4 and T5)</time_frame>
        <population>Intention to Treat Set (ITT): all randomized patients who received at least one dose of study treatment.
The number of participants analyzed in Visit T5 is less then Visit T1 since 8 participants dropped from the study before Visit T5.</population>
        <group_list>
          <group group_id="O1">
            <title>Bifidobacterium BB-12®</title>
            <description>patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
Bifidobacterium, BB-12® (Bifidolactis Infant)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
Bifidolactis Infant Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Bowel Evacuation - Stool Consistency</title>
          <description>Stool consistency was evaluated as the number and the proportion of patients who reported at least one stool sample of each type per week, according to Bristol scale as follows:
Type A = separate hard lumps, like nuts (hard to pass) Type B = sausage-shaped, but lumpy Type C = Like a sausage but with cracks on its surface Type D = like a sausage or snake, smooth and soft Only a descriptive statistics Type E = soft blobs with clear-cut edges (passed easily) Type F = fluffy pieces with ragged edges, a mushy stool Type G = watery, no solid pieces (entirely liquid). Patients could report more than one stool consistency per day then the sum of the &quot;Count of Participants&quot; for each group at each visit could be Greater then the &quot;Overall Number of Participants Analyzed&quot;</description>
          <population>Intention to Treat Set (ITT): all randomized patients who received at least one dose of study treatment.
The number of participants analyzed in Visit T5 is less then Visit T1 since 8 participants dropped from the study before Visit T5.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T1: Patients with at least 1 stool of type C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: Patients with at least one stool of type D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: Patients with at least one stool of type E</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: Patients with at least one stool of type F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: Patients with at least one stool of type G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: Patients with at least one stool of type C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: Patients with at least one stool of type D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: Patients with at least one stool of type E</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: Patients with at least one stool of type F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: Patients with at least one stool of type G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: Patients with at least one stool of type C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: Patients with at least one stool of type D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: Patients with at least one stool of type E</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: Patients with at least one stool of type F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: Patients with at least one stool of type G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: Patients with at least one stool of type C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: Patients with at least one stool of type D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: Patients with at least one stool of type E</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: Patients with at least one stool of type F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: Patients with at least one stool of type G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T5: Patients with at least one stool of type C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T5: Patients with at least one stool of type D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T5: Patients with at least one stool of type E</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T5: Patients with at least one stool of type F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T5: Patients with at least one stool of type G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infant's Mood</title>
        <description>The infant's mood (calm, asleep, agitated, irritable) was collected daily in the diary and was evaluated as the number and the proportion of infants who reported at least one mood of each type per week.
Patients could report more than one mood per day then the sum of the &quot;Count of Participants&quot; for each group at each visit could be greater then the &quot;Overall Number of Participants Analyzed&quot;.</description>
        <time_frame>at each weekly visit from baseline (Visit T1, T2, T3, T4 and T5)</time_frame>
        <population>Intention to Treat Set (ITT): all randomized patients who received at least one dose of study treatment. The number of participants analyzed in Visit T5 is less then Visit T1 since 8 participants dropped from the study before Visit T5</population>
        <group_list>
          <group group_id="O1">
            <title>Bifidobacterium BB-12®</title>
            <description>patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
Bifidobacterium, BB-12® (Bifidolactis Infant)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
Bifidolactis Infant Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Infant's Mood</title>
          <description>The infant's mood (calm, asleep, agitated, irritable) was collected daily in the diary and was evaluated as the number and the proportion of infants who reported at least one mood of each type per week.
Patients could report more than one mood per day then the sum of the &quot;Count of Participants&quot; for each group at each visit could be greater then the &quot;Overall Number of Participants Analyzed&quot;.</description>
          <population>Intention to Treat Set (ITT): all randomized patients who received at least one dose of study treatment. The number of participants analyzed in Visit T5 is less then Visit T1 since 8 participants dropped from the study before Visit T5</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T1: Pts with at least one mood equal to Calm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: Pts. with at least one mood equal to Asleep</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: Pts. with at least one mood equal to Agitated</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1: Pts. with at least one mood equal to Irritable</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: Pts. with at least one mood equal to Calm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: Pts. with at least one mood equal to Asleep</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: Pts. with at least one mood equal to Agitated</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: Pts. with at least one mood equal to Irritable</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: Pts. with at least one mood equal to Calm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: Pts. with at least one mood equal to Asleep</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: Pts. with at least one mood equal to Agitated</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: Pts. with at least one mood equal to Irritable</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: Pts. with at least one mood equal to Calm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: Pts. with at least one mood equal to Asleep</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: Pts. with at least one mood equal to Agitated</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4: Pts. with at least one mood equal to Irritable</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T5: Pts. with at least one mood equal to Calm</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T5: Pts. with at least one mood equal to Asleep</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T5: Pts. with at least one mood equal to Agitated</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T5: Pts. with at least one mood equal to Irritable</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infant's Sleep</title>
        <description>Duration of sleep (in minutes) was collected daily in the diary during the entire study period. Mean daily duration of sleep by week was defined as the mean of the daily durations during the selected week and was described by means of descriptive statistics for continuous data.</description>
        <time_frame>at each weekly visit from baseline (Visit T1, T2, T3, T4 and T5)</time_frame>
        <population>Intention to Treat Set (ITT): all randomized patients who received at least one dose of study treatment. The number of participants analyzed in Visit T5 is less then Visit T1 since 8 participants dropped from the study before Visit T5</population>
        <group_list>
          <group group_id="O1">
            <title>Bifidobacterium BB-12®</title>
            <description>patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
Bifidobacterium, BB-12® (Bifidolactis Infant)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
Bifidolactis Infant Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Infant's Sleep</title>
          <description>Duration of sleep (in minutes) was collected daily in the diary during the entire study period. Mean daily duration of sleep by week was defined as the mean of the daily durations during the selected week and was described by means of descriptive statistics for continuous data.</description>
          <population>Intention to Treat Set (ITT): all randomized patients who received at least one dose of study treatment. The number of participants analyzed in Visit T5 is less then Visit T1 since 8 participants dropped from the study before Visit T5</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit T1 - baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="678.14" spread="96.13"/>
                    <measurement group_id="O2" value="693.62" spread="121.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="687.47" spread="113.41"/>
                    <measurement group_id="O2" value="696.68" spread="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="722.37" spread="116.30"/>
                    <measurement group_id="O2" value="711.99" spread="128.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="725.76" spread="112.54"/>
                    <measurement group_id="O2" value="725.14" spread="131.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="713.20" spread="98.97"/>
                    <measurement group_id="O2" value="738.61" spread="141.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infant's Temper</title>
        <description>Duration of temper episodes (in minutes) was collected daily in the diary during the entire study period. Mean daily duration of temper episodes by week was defined as the mean of the daily durations during the selected week and was described by means of descriptive statistics for continuous data.</description>
        <time_frame>at each weekly visit from baseline (Visit T1, T2, T3, T4 and T5)</time_frame>
        <population>Intention to Treat Set (ITT): all randomized patients who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Bifidobacterium BB-12®</title>
            <description>patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
Bifidobacterium, BB-12® (Bifidolactis Infant)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
Bifidolactis Infant Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Infant's Temper</title>
          <description>Duration of temper episodes (in minutes) was collected daily in the diary during the entire study period. Mean daily duration of temper episodes by week was defined as the mean of the daily durations during the selected week and was described by means of descriptive statistics for continuous data.</description>
          <population>Intention to Treat Set (ITT): all randomized patients who received at least one dose of study treatment.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit T1 - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.82" spread="36.31"/>
                    <measurement group_id="O2" value="138" spread="34.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.61" spread="45.59"/>
                    <measurement group_id="O2" value="117.24" spread="58.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.48" spread="47.96"/>
                    <measurement group_id="O2" value="84.33" spread="46.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.71" spread="54.79"/>
                    <measurement group_id="O2" value="84.89" spread="58.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.79" spread="42.45"/>
                    <measurement group_id="O2" value="72.96" spread="40.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infant's Feeding</title>
        <description>Duration of feeding (in minutes) was collected daily in the diary during the entire study period. Mean daily feeding time by week was defined as the mean of the daily durations during the selected week and was described by means of descriptive statistics for continuous data.</description>
        <time_frame>at each weekly visit from baseline (Visit T1, T2, T3, T4 and T5)</time_frame>
        <population>Intention to Treat Set (ITT): all randomized patients who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Bifidobacterium BB-12®</title>
            <description>patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
Bifidobacterium, BB-12® (Bifidolactis Infant)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
Bifidolactis Infant Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Infant's Feeding</title>
          <description>Duration of feeding (in minutes) was collected daily in the diary during the entire study period. Mean daily feeding time by week was defined as the mean of the daily durations during the selected week and was described by means of descriptive statistics for continuous data.</description>
          <population>Intention to Treat Set (ITT): all randomized patients who received at least one dose of study treatment.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit T1 - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187.72" spread="35.95"/>
                    <measurement group_id="O2" value="177.72" spread="34.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186.13" spread="63.37"/>
                    <measurement group_id="O2" value="188.98" spread="32.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.80" spread="55.16"/>
                    <measurement group_id="O2" value="185.98" spread="30.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.31" spread="47.85"/>
                    <measurement group_id="O2" value="182.22" spread="28.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.47" spread="38.55"/>
                    <measurement group_id="O2" value="182.26" spread="27.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Calprotectin</title>
        <description>Evaluation of calprotectin levels in fecal samples</description>
        <time_frame>at 7 days (Visit T1 - baseline) and 28 days from the baseline (Visit T5)</time_frame>
        <population>The analysis Population includes all participants for wich an evaluable fecal sample was available at Visit T1 and Visit T5</population>
        <group_list>
          <group group_id="O1">
            <title>Bifidobacterium BB-12®</title>
            <description>patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
Bifidobacterium, BB-12® (Bifidolactis Infant)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
Bifidolactis Infant Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Calprotectin</title>
          <description>Evaluation of calprotectin levels in fecal samples</description>
          <population>The analysis Population includes all participants for wich an evaluable fecal sample was available at Visit T1 and Visit T5</population>
          <units>mM/Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit T1 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="667.76" spread="162.06"/>
                    <measurement group_id="O2" value="658.47" spread="112.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="802.64" spread="131.33"/>
                    <measurement group_id="O2" value="915.41" spread="106.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beta-defensin Type 2</title>
        <description>Evaluation of Beta-defensin type 2 levels in fecal samples</description>
        <time_frame>at 7 days (Visit T1 - baseline) and 28 days from the baseline (Visit T5)</time_frame>
        <population>The analysis Population includes all participants for wich an evaluable fecal sample was available at Visit T1 and Visit T5</population>
        <group_list>
          <group group_id="O1">
            <title>Bifidobacterium BB-12®</title>
            <description>patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
Bifidobacterium, BB-12® (Bifidolactis Infant)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
Bifidolactis Infant Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Beta-defensin Type 2</title>
          <description>Evaluation of Beta-defensin type 2 levels in fecal samples</description>
          <population>The analysis Population includes all participants for wich an evaluable fecal sample was available at Visit T1 and Visit T5</population>
          <units>ng/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit T1 - baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.50" spread="10.92"/>
                    <measurement group_id="O2" value="69.41" spread="7.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.34" spread="43.79"/>
                    <measurement group_id="O2" value="127.97" spread="35.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LL37 Peptide</title>
        <description>Evaluation of LL37 peptide levels in fecal samples</description>
        <time_frame>at 7 days (Visit T1 - baseline) and 28 days from the baseline (Visit T5)</time_frame>
        <population>The analysis Population includes all participants for wich an evaluable fecal sample was available at Visit T1 and Visit T5</population>
        <group_list>
          <group group_id="O1">
            <title>Bifidobacterium BB-12®</title>
            <description>patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
Bifidobacterium, BB-12® (Bifidolactis Infant)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
Bifidolactis Infant Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>LL37 Peptide</title>
          <description>Evaluation of LL37 peptide levels in fecal samples</description>
          <population>The analysis Population includes all participants for wich an evaluable fecal sample was available at Visit T1 and Visit T5</population>
          <units>ng/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit T1 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.50" spread="0.82"/>
                    <measurement group_id="O2" value="5.37" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.65" spread="1.15"/>
                    <measurement group_id="O2" value="6.07" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Chain Fatty Acids - Butyrate</title>
        <description>Evaluation of Butyrate levels in fecal samples</description>
        <time_frame>at 7 days (Visit T1 - baseline) and 28 days from the baseline (Visit T5)</time_frame>
        <population>The analysis Population includes all participants for wich an evaluable fecal sample was available at Visit T1 and Visit T5</population>
        <group_list>
          <group group_id="O1">
            <title>Bifidobacterium BB-12®</title>
            <description>patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
Bifidobacterium, BB-12® (Bifidolactis Infant)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
Bifidolactis Infant Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Short Chain Fatty Acids - Butyrate</title>
          <description>Evaluation of Butyrate levels in fecal samples</description>
          <population>The analysis Population includes all participants for wich an evaluable fecal sample was available at Visit T1 and Visit T5</population>
          <units>mM/Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit T1 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.14"/>
                    <measurement group_id="O2" value="0.17" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.49"/>
                    <measurement group_id="O2" value="0.32" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secretory Immunoglobulin A (SIgA)</title>
        <description>Secretory immunoglobulin A (SIgA) levels in fecal samples</description>
        <time_frame>at 7 days (Visit T1 - baseline) and 28 days from the baseline (Visit T5)</time_frame>
        <population>The analysis Population includes all the participants for wich an evaluable fecal sample was available at Visit T1 and Visit T5</population>
        <group_list>
          <group group_id="O1">
            <title>Bifidobacterium BB-12®</title>
            <description>patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
Bifidobacterium, BB-12® (Bifidolactis Infant)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
Bifidolactis Infant Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Secretory Immunoglobulin A (SIgA)</title>
          <description>Secretory immunoglobulin A (SIgA) levels in fecal samples</description>
          <population>The analysis Population includes all the participants for wich an evaluable fecal sample was available at Visit T1 and Visit T5</population>
          <units>microg/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit T1 - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.79" spread="21.71"/>
                    <measurement group_id="O2" value="86.55" spread="12.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit T5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.65" spread="37.95"/>
                    <measurement group_id="O2" value="192.01" spread="27.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 weeks starting from the patient enrollment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bifidobacterium BB-12®</title>
          <description>patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
Bifidobacterium, BB-12® (Bifidolactis Infant)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
Bifidolactis Infant Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>LAURA PATRUCCO</name_or_title>
      <organization>SOFAR S.p.A</organization>
      <phone>+390202 909 362291</phone>
      <email>laura.patrucco@sofarfarm.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

